Researchers have developed MILTON, an AI tool that analyzes routine patient test data to predict early signs of over 1,000 diseases, such as Alzheimer’s and kidney disease, long before symptoms appear. AstraZeneca, which developed the tool, aims to accelerate early interventions and treatments. While MILTON shows “exceptional” predictive performance for 121 diseases, experts caution about its ethical use and potential misuse by insurers or employers without consent. Further work is needed before MILTON can be used clinically.
Keep Reading
Add A Comment